Inner Circle Follows the MDM Group Inc., (MDDM; OTCBB)
Bill Ridley, well known conference speaker and financial journalist, has
begun following MDDM in his market letter, the Inner Circle.
Ridley says I am very enthused about a new product which may prove to be the
greatest medical discovery for cancer treatment in history. Of major
interest to shareholders are the numbers relating to market potential. They
are astounding. See below for more details.
Following are further excerpts from Ridley's analysis.
May, 17 1999 - MDM Group Inc.-A Potential Breakthrough Discovery For Cancer
Treatment THE INNER CIRCLE NEWSLETTER Special Report, May 1999MDM Group Inc.
Symbol: MDDM, (NASD, OTC BB)Shares Issued: 10,150,000Warrants: 800,000Float:
750,000For an investor package call 1-888-823-5767
A POTENTIAL BREAKTHROUGH DISCOVERY FOR CANCER!
Cancer has long been the bane of our society having been responsible for
countless cases of pain and suffering. Despite the efforts of many
researchers and organizations, cancer is the second leading cause of death
in the United States. For cancer survivors, the emotional and often the
financial turmoil which must be endured is unacceptably high.For these
reasons particularly, I am very enthused about a new product which may prove
to be the greatest medical discovery for cancer treatment in history.
BIOLOGIC RESPONSE MODIFIERS
Since the early 1980's Dr. Richard Urban has been working on a cancer
treatment product called Biologic Response Modifiers, internally named NPP5
/ NPP5A . Completion of the Phase I clinical trials looked very
encouraging.NPP5 was trialed on 110 terminal cancer patients, considered
untreatable, who had failed prior therapy. With only a limited amount of
time to live, these patients were thought to be beyond hope. Amazingly, the
treatment produced a 41% response rate with these "untreatable" patients.
Considering that the researchers didn't know the best therapeutic regime to
use, results like these are unheard of. Current genetically engineered drugs
such as Interferon and Interleukin-2, at $15,000 to $20,000 per treatment,
do not achieve such a high response rate against a broad spectrum of
cancers.
Another surprise was that the side effects from NPP5 were limited. A patient
may have a mild flu like symptoms, a low grade fever, or a small degree of
swelling. For many patients, NPP5 allowed for an enhanced quality of life.
This is a far cry from the harsh chemotherapy treatments.The first patient
Dr. Urban treated had advanced breast cancer and a history of alcoholism.
Her right side had a radical mastectomy and on her left breast was a
softball sized tumor. Her life expectancy was about six months."In a couple
of weeks she had 85% regression verified by biopsy in the right chest wall
and in the left chest the tumor shrunk down to the size of a marble. She was
treated only once and she remained stable for the next two years. The
oncologist couldn't believe it" Dr. Urban stated.This truly could be a God
send for cancer patients. We all know of the terrible physical toll
conventional therapies have on cancer patients.
CANCERS TREATED
NPP5 has been tested on a broad range of cancer tumors including: breast,
basil cell, non-small cell lung, prostate, Hodgkin's disease, non-Hodgkin's
lymphoma, glioblastoma, pancreatic, renal cell, colon rectal, melanoma,
adenocarcinoma (lung), muco-epidermoid, malignant fibrohistiocytoma, and
thymoma. Administration is by injection once a week for three weeks.Thanks
to Bill Clinton and the FDA, a new policy was established which allows a
"fast track" program for Cancer and HIV drugs. An added benefit for MDM and
Dr Urban's group is another new policy called "Orphan Status." Now smaller
companies who are treating smaller-sized patient groups of under 50,000
cases per year can conduct trials on smaller numbers of patients than is
usually required. Also, it would not be neccessary to do phase III trials.
MARKET POTENTIAL
An estimated 9 million people worldwide will get cancer this year. The
potential for a product which exhibits a high degree of efficacy and a low
side effect profile would undoubtedly be highly sought after.The cost per
treatment for the Biologic Response Modifiers is projected to be about 10%
of the Interferon or Interleukin-2 treatment costs or $1500-$2000.If NPP5/A
becomes commercially available, here is an example of their earnings
potential based on 2% of the expected 9 million new cancer patients expected
this year.
(Note: Dr. Urban's work is primarily concerned with successfully helping
victims of cancer. The company expects that half of their production will be
set aside for humanitarian purposes.)
Patients treated: 180,000
Average treatments: 6
Treatments annually: 1,080,000
Net profit per treatment: $1500
Total net profits: $1.620 billion
MDDM, {NASD OTC BB} (50%) $810,000,000
Shares: 11 million
EPS: $73.64
Average Biotech P/E: 40
Projected Price: $2,945.60 (assuming the stock doesn't split)
Please understand that these numbers are forward looking and do not construe
anything other than potential best-guess scenarios.
For the complete report you may call investor relations at 888-823-5767 or
see www.billridley.com |
